CIP
MACK

Convergence Investment Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Convergence Investment Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,276
Closed -$493K – 448
2015
Q1 		$493K Sell
5,276
-9,072
-63% -$772K 0.07% 314
2014
Q4 		$1.28M Buy
+14,348
New +$1.05M 0.17% 208

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Convergence Investment Partners's MACK Position: Q2 2015 in Review

Convergence Investment Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2015, closing a stake of 5,276 shares — an estimated $493K sold.

Convergence Investment Partners first reported a position in MACK in Q4 2014 and held it in 2 quarters. The position peaked at $1.28M in Q4 2014. 150 funds tracked by Wall St. Rank hold MACK as of Q2 2015.

  • Convergence Investment Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Convergence Investment Partners sold 5,276 Merrimack Pharmaceuticals, Inc. shares in Q2 2015, an estimated $493K.
  • Convergence Investment Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
  • Convergence Investment Partners's Merrimack Pharmaceuticals, Inc. position peaked at $1.28M in Q4 2014.
  • 150 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2015.

Based on Convergence Investment Partners's 13F filing for Q2 2015, filed 5 Aug 2015.